SCHEMBL2904469

SCHEMBL2904469

CC(C)(C)OC(=O)N1CCC(C)(C)C(O)C1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NR1H2 P55055 1/20 0.43
HPGD P15428 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
EPHX2 P34913 1/20 0.41
RECQL P46063 1/20 0.40
EPHX1 P07099 1/20 0.40
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
HSD11B1 P28845 2/20 0.39
GPR119 Q8TDV5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30186133 1.00 USP2 (0.45) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL23578678 0.89 USP2 (0.44) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL29959344 0.89 USP2 (0.44) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL29959428 0.89 USP2 (0.44) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL16903460 0.85 HPGD (0.51) USP2SMN1; SMN2HPGDALDH1A1MAPT
SCHEMBL9942499 0.85 USP2 (0.44) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL734925 0.85 USP2 (0.44) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL733741 0.85 USP2 (0.44) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL22776027 0.85 NR1H2 (0.44) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL17499914 0.85 NR1H2 (0.44) USP2SMN1; SMN2NR1H2HPGDEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117062811-A 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and medical use thereof 诺华股份有限公司 2023-11-14 CN disclosed
EP-2010506-B1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS HOFFMANN LA ROCHE (CH) 2010-08-04 EP disclosed
US-7632829-B2 Diazepan derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-15 US disclosed
EP-2010506-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-Roche AG (CH) 2009-01-07 EP disclosed
WO-2007122103-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-01 WO disclosed
US-20070249589-A1 Novel diazepan derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249589-A1 Novel diazepan derivatives CCR3, CCR1, CCR10 USP2 3011/4885SMN1; SMN2 2573/4885NR1H2 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.